Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

LSE:AREC Shares Jump 9.24% — Is AT278 Becoming Arecor's Biggest Healthcare Catalyst?

Arecor Therapeutics has gained9.24% on 17 August 2026, bringing LSE:AREC back into focus among UK-listed healthcare and biotechnology stocks.

Ankur Sharma | 17 August 2026

Cambridge Cognition LSE:COG in focus as investors weigh debt-free balance sheet against continued investment requirements

Cambridge Cognition Holdings Plc LSE:COG is attracting renewed attention after its shares declined6.06% on August 17, 2026.

Ankur Sharma | 17 August 2026

GSK's Vaccine and Specialty Medicine Bets Keep Paying Off

GSK PLC shares were1.10% higher at 1,837.50p today, 17 August 2026, according to the market data provided. The gain reflects continued investor confidence in the group's pharmaceutical and vaccines pipeline.

Divya Sood | 17 August 2026

AstraZeneca's Oncology Pipeline Keeps Firing on All Fronts

AstraZeneca PLC shares were1.00% higher at 11,574.00p today, 17 August 2026, according to the market data provided. The gain reflects continued investor confidence in the group's broad oncology and biopharmaceutical pipeline.

Divya Sood | 17 August 2026

hVIVO (HVO) Share Price: Order Book Doubles to £65m Ahead of Make-or-Break H2

hVIVO (LSE:HVO) used its 23 July 2026 half-year trading update to reframe a difficult six months as a story about timing rather than lost demand. The headline number was the order book, which the company said had more than doubled to roughly £65m, up …

Divya Sood | 17 August 2026

Inspiration Healthcare (IHC) Share Price: Revenue Up 24% as Neonatal Pivot Pays Off

Inspiration Healthcare (LSE:IHC)'s full-year results for the year to 31 January 2026, published in June 2026, showed aBusinessthat has both grown strongly and sharpened its strategic focus. The AIM-listed medical-technology group reportedRevenueup 24% and used the results to confirm its pivot towards neonatal intensive …

Divya Sood | 17 August 2026

Avacta (AVCT): FDA Agrees a Single-Trial Path to Full Approval for Cancer Drug AVA6000

Avacta (LSE:AVCT) Group, the AIM-listed oncology and diagnostics company, secured an important regulatory milestone in June 2026 when the US Food and Drug Administration agreed that a single pivotal clinical trial could be sufficient to support full approval of its lead cancer drug, AVA6000 …

Divya Sood | 17 August 2026

hVIVO (LSE:HVO): Order Book Doubles to £65m as the Challenge-Trial Specialist Bets Everything on a Second-Half Rebound

hVIVO (LSE:HVO) used its 23 July 2026 half-year trading update to reframe a difficult six months as a story about timing rather than lost demand. The headline number was the order book, which the company said had more than doubled to roughly £65m, up …

Ankur Sharma | 17 August 2026

Inspiration Healthcare (LSE:IHC): Revenue Jumps 24% as the Neonatal Pivot and Falling Debt Reshape the Investment Case

Inspiration Healthcare (LSE:IHC)'s full-year results for the year to 31 January 2026, published in June 2026, showed aBusinessthat has both grown strongly and sharpened its strategic focus. The AIM-listed medical-technology group reportedRevenueup 24% and used the results to confirm its pivot towards neonatal intensive …

Ankur Sharma | 17 August 2026

AstraZeneca and the $400bn Merger That Never Was — Where Britain's Pharma Giant Goes Next

For roughly seventy-two hours in early August, the City entertained the idea that Britain's most valuable listed company was about to disappear into the largest pharmaceutical merger in history. The Financial Times reported that AstraZeneca (LSE:AZN) had held talks with New York's Bristol Myers …

Ankur Sharma | 17 August 2026
Support

Hi! How can we help you today?

Loading…